Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Kerstin Röhss"'
Autor:
Philip Katz, Peter J. Kahrilas, David A. Johnson, Tore Lind, Kerstin Röhss, Barry Traxler, Vincent Hugo, John Dent
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 8 (2015)
Objectives: In mild gastroesophageal reflux disease, which accounts for the great majority of cases, the major burden of reflux occurs during daytime hours, after food intake. The aim of these analyses was to evaluate intragastric pH control during t
Externí odkaz:
https://doaj.org/article/e6da1e98881349a2a01324852470fa7b
Publikováno v:
Alimentary Pharmacology & Therapeutics. 32:1249-1256
Aliment Pharmacol Ther 2010; 32: 1249–1256 Summary Background Symptoms of gastro-oesophageal reflux disease (GERD) may persist despite daily treatment with a proton pump inhibitor (PPI). Aim To compare the pharmacodynamic effect of various esomepra
Autor:
Kerstin Röhss, Philip O. Katz, Ola Junghard, David A. Johnson, Peter Nagy, Magnus Åstrand, Doug Levine
Publikováno v:
Journal of Clinical Gastroenterology. 44:475-478
Proton pump inhibitors (PPIs) are the preferred treatment for maintenance of healed reflux esophagitis (RE). However, little is known regarding the relationship between prevention of RE relapse and degree of gastric acid suppression. The aim of this
Autor:
Peter Nagy, D. Levine, David W. Johnson, Ola Junghard, Magnus Åstrand, Philip O. Katz, Kerstin Röhss
Publikováno v:
Alimentary Pharmacology & Therapeutics. 32:443-447
Aliment Pharmacol Ther 2010; 32: 443–447 Summary Background In patients with Los Angeles (LA) grade C or D oesophagitis, a positive relationship has been established between the duration of intragastric acid suppression and healing. Aim To determin
Autor:
Tore Lind, Mia Fjellman, Göran Eckerwall, Kerstin Röhss, Anna Backlund, Clive H. Wilder-Smith
Publikováno v:
Clinical Drug Investigation. 28:333-343
Background and objective: In patients with gastro-oesophageal reflux disease (GORD), dose escalation or drug switching may be considered in those with symptoms that persist despite standard-dose proton pump inhibitor (PPI) therapy. This study set out
Autor:
John Dent, David A. Johnson, Philip O. Katz, Barry Traxler, Vincent Hugo, Peter J. Kahrilas, Tore Lind, Kerstin Röhss
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 8 (2015)
Objectives: In mild gastroesophageal reflux disease, which accounts for the great majority of cases, the major burden of reflux occurs during daytime hours, after food intake. The aim of these analyses was to evaluate intragastric pH control during t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a9ee222e1c20e8349d55db4144fcc3a
https://europepmc.org/articles/PMC4622284/
https://europepmc.org/articles/PMC4622284/
Autor:
Mathias Liljeblad, T Andersson, B A Persson, Kerstin Röhss, Mohammed Hassan-Alin, Mohammad Niazi
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 44:119-127
Objective A combination of esomeprazole, amoxicillin and clarithromycin may be used for Helicobacter pylori eradication. We explored the potential for interactions between these drugs. Methods In 2 randomized, 4-way crossover studies, healthy CYP2C19
Autor:
Marie Lundgren, Kerstin Röhss, Lars Nyman, Clive H. Wilder-Smith, Patrik Bondarov, Mohammad Niazi, Henrik Ahlbom
Publikováno v:
European Journal of Gastroenterology & Hepatology. 17:191-197
Objectives Two studies compared the effects of intravenous (i.v.) and oral esomeprazole (40 mg and 20 mg) on gastric acid suppression and pharmacokinetics after both single (day 1) and repeated (day 5) dosing. Methods Two randomized, two-way, cross-o
Autor:
Henrik Ahlbom, Kerstin Röhss, Catharina Nilsson-Pieschl, Mohammed Hassan-Alin, Christina Lundin, Clive H. Wilder-Smith, Patrik Bondarov, Mohammad Niazi
Publikováno v:
Clinical Drug Investigation. 25:517-525
Background: An intravenous (IV) formulation of esomeprazole has been developed as an alternative to oral administration. To meet the needs of different clinical situations it would be preferable if an IV dose could be administered as either an inject
Publikováno v:
European Journal of Clinical Pharmacology. 60:779-784
To investigate the pharmacokinetics of S-omeprazole (esomeprazole), R-omeprazole and racemic omeprazole following single and repeated oral doses of 20 mg and 40 mg of each compound in healthy male and female subjects.In an open, randomised, three-way